Status:
COMPLETED
Effect of Liraglutide on Absorption of Paracetamol in Subjects With Type 2 Diabetes
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
Brief Summary
This trial is conducted in Europe. The aim of this trial is to to investigate if there is a drug-drug interaction between liraglutide and paracetamol (Benuron®) and to investigate the effect of liragl...
Eligibility Criteria
Inclusion
- Type 2 diabetes mellitus
- Diet-treated subjects with type 2 diabetes with HbA1c 7.5-9.5 %
- Subjects with type 2 diabetes in oral anti-diabetic drug (OAD) monotherapy treated with metformin or alpha-glucosidase inhibitors with HbA1c 7.0-9.5%
- Body mass index (BMI) 18.5-40 kg/m\^2
- Subjects should have a stable body weight for at least 3 months prior to screening (as judged by the Investigator)
Exclusion
- Impaired liver function
- Impaired renal function
- Clinically significant active cardiovascular disease including history of myocardial infarction within the last 6 months and/or heart failure
- Any clinically significant abnormal ECG (electrocardiogram)
- Uncontrolled treated/untreated hypertension
- Recurrent severe hypoglycaemia as judged by the Investigator
- Active hepatitis B and/or active hepatitis C
- Positive human immunodeficiency virus (HIV) antibodies
- Known or suspected allergy to trial product(s) or related products
Key Trial Info
Start Date :
October 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2007
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT01517555
Start Date
October 1 2006
End Date
May 1 2007
Last Update
January 26 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Neuss, Germany, 41460